Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters








Database
Publication year range
1.
Phys Rev Lett ; 133(11): 111802, 2024 Sep 13.
Article in English | MEDLINE | ID: mdl-39331997

ABSTRACT

The NA62 experiment at CERN, configured in beam-dump mode, has searched for dark photon decays in flight to electron-positron pairs using a sample of 1.4×10^{17} protons on dump collected in 2021. No evidence for a dark photon signal is observed. The combined result for dark photon searches in lepton-antilepton final states is presented and a region of the parameter space is excluded at 90% confidence level, improving on previous experimental limits for dark photon mass values between 50 and 600 MeV/c^{2} and coupling values in the range 10^{-6} to 4×10^{-5}. An interpretation of the e^{+}e^{-} search result in terms of the emission and decay of an axionlike particle is also presented.

2.
Phys Rev Lett ; 127(13): 131802, 2021 Sep 24.
Article in English | MEDLINE | ID: mdl-34623867

ABSTRACT

Searches for the lepton number violating K^{+}→π^{-}µ^{+}e^{+} decay and the lepton flavor violating K^{+}→π^{+}µ^{-}e^{+} and π^{0}→µ^{-}e^{+} decays are reported using data collected by the NA62 experiment at CERN in 2017-2018. No evidence for these decays is found and upper limits of the branching ratios are obtained at 90% confidence level: B(K^{+}→π^{-}µ^{+}e^{+})<4.2×10^{-11}, B(K^{+}→π^{+}µ^{-}e^{+})<6.6×10^{-11} and B(π^{0}→µ^{-}e^{+})<3.2×10^{-10}. These results improve by 1 order of magnitude over previous results for these decay modes.

3.
Pediatr Med Chir ; 16(1): 93-4, 1994.
Article in Italian | MEDLINE | ID: mdl-8029101

ABSTRACT

The Authors describe a case of congenital coagulation factor V deficiency with severe prenatal intraventricular hemorrhage. Factor V is an essential enzyme catalysing the process of thrombin generation. Low levels of enzyme were also found in both parents, who demonstrate subclinic alterations of coagulation parameters. The severe deficiency of factor V in the newborn (8%) caused frequent and severe intracranial and gastric hemorrhages that brought newborn to death in few weeks.


Subject(s)
Cerebral Hemorrhage/etiology , Factor V Deficiency , Fetal Diseases , Blood Coagulation Tests , Factor V Deficiency/complications , Factor V Deficiency/diagnosis , Gastrointestinal Hemorrhage/etiology , Hematoma, Subdural/etiology , Humans , Infant, Newborn , Magnetic Resonance Imaging , Male
4.
Pediatr Med Chir ; 13(5): 519-22, 1991.
Article in Italian | MEDLINE | ID: mdl-1788114

ABSTRACT

The Authors describe a case of William-Beuren Syndrome, also know as "Fanconi-Schlesinger Syndrome" or "Idiopathic Hypercalcaemia, supravalvular aortic stenosis, elfin facies syndrome". Irritability and chronic constipation are early features. Hypercalcaemia may occur in infancy but rarely after 1 year age. The facies is characteristic. Supravalvular aortic stenosis is the most frequent cardiac abnormality. Other common features are short stature, mental retardation and significant behavioural disorders. In this case report typical facies, short stature, behavioural disorders are associated with epilepsy in early years of life. Hypercalcaemia or cardiovascular malformation were not found.


Subject(s)
Aortic Valve Stenosis/congenital , Face/abnormalities , Aortic Valve Stenosis/diagnosis , Humans , Infant, Newborn , Male , Syndrome
5.
Pediatr Med Chir ; 11(4): 467-9, 1989.
Article in Italian | MEDLINE | ID: mdl-2694110

ABSTRACT

A case of Hypohidrotic Ectodermal Dysplasia is reported. Inability of sweating is associated with characteristic craniofacial anomalies, oligo-anodontia and rare, thin hair. X-linked and autosomal inheritance are both supposed.


Subject(s)
Ectodermal Dysplasia/genetics , Anodontia , Humans , Infant , Male , Phenotype , Syndrome
6.
Eur J Clin Pharmacol ; 34(1): 25-8, 1988.
Article in English | MEDLINE | ID: mdl-3282894

ABSTRACT

The safety and efficacy of a single daily dose of fenofibrate (200 mg) have been evaluated in 12 Type IIB hyperlipidaemic patients in a three-month study. At the same time the pharmacokinetics was studied to check whether this new dosage schedule would give a therapeutic plasma levels of fenofibrate. At the single daily dose of 200 mg, fenofibrate was highly effective, very well tolerated, and it reached therapeutic plasma levels without accumulation. It appears that fenofibrate can usefully be employed at this dosage in hyperlipidaemia, especially since patient compliance is better when only one daily dose need be taken.


Subject(s)
Anticholesteremic Agents/administration & dosage , Fenofibrate/administration & dosage , Hyperlipoproteinemia Type II/drug therapy , Hypolipidemic Agents/administration & dosage , Lipoproteins/blood , Propionates/administration & dosage , Adult , Anticholesteremic Agents/blood , Anticholesteremic Agents/pharmacokinetics , Anticholesteremic Agents/therapeutic use , Capsules , Clinical Trials as Topic , Drug Administration Schedule , Female , Fenofibrate/analogs & derivatives , Fenofibrate/blood , Fenofibrate/pharmacokinetics , Fenofibrate/therapeutic use , Humans , Hyperlipoproteinemia Type II/blood , Hypolipidemic Agents/blood , Hypolipidemic Agents/pharmacokinetics , Hypolipidemic Agents/therapeutic use , Male , Middle Aged , Patient Compliance
SELECTION OF CITATIONS
SEARCH DETAIL